Safety and immunogenicity of a killed Leishmania (L.) amazonensis vaccine against cutaneous leishmaniasis in Colombia: Arandomized controlled trial

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 94, Issue 6, 2000, Pages 698-703

  Vélez, Ivan Dario ^a   Del Pilar Agudelo, Sonia ^a   Arbelaez, Maria Patricia ^a   Gilchrist, Katherine ^a   Robledo, Sara Maria ^a   Puerta, Juan Alberto ^a   Zicker, Fabio ^b   Berman, Jonathan ^c   Modabber, Farrokh ^b  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b WORLD BANK   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

BCG adjuvant; Clinical trial; Colombia; Cutaneous leishmaniasis; Immune responses; Leishmania amazonensis; Safety; Vaccine

Indexed keywords

ADJUVANT; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BCG VACCINE; CREATININE; CYTOKINE; GAMMA INTERFERON; GLUCOSE; HEMOGLOBIN; INACTIVATED VACCINE; INTERLEUKIN 10; LEISHMANIA VACCINE; MONOCLONAL ANTIBODY; PARASITE ANTIBODY; PARASITE ANTIGEN; PLACEBO; RECOMBINANT GAMMA INTERFERON;

ADULT; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; COLOMBIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG MIXTURE; DRUG SAFETY; ERYTHEMA; FEVER; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INJECTION PAIN; LEISHMANIA; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POPULATION RESEARCH; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SKIN LEISHMANIASIS; SKIN TEST; SKIN ULCER; TH1 CELL; TREATMENT OUTCOME;

EID: 0033660439     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-9203(00)90239-6     Document Type: Article

References (20)

1. Controlled field trial of a vaccine against New World cutaneous leishmaniasis
2. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: Safety, immunogenicity and efficacy during the first 12 months of follow up
3. Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers
4. Chemotherapy for leishmaniasis: Biochemical mechanisms, clinical efficacy and future strategies
5. Immune response in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG. I. Skin test reactivity, T cell proliferation and interferon gamma production
6. Leishmaniasis: Immunological and clinical aspects and vaccines in Venezuela
7. Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis
8. Stepwise safety trial of a killed Leishmania vaccine in Iran
9. Vaccine for prophylaxis and immunotherapy, Brazil
10. A field trial of a vaccine against American dermal leishmaniasis
11. Vaccines against leishmaniasis
12. A randomized, double blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran
13. Practical progress and new drugs for changing patterns of leishmaniasis
14. The relationship of Leishmania braziliensis subspecies and immune response to disease expression in New World leishmaniasis
15. Immune response in healthy volunteers vaccinated with BCG plus killed leishmanial promastigotes: Antibody response to mycobacterial and leishmanial antigens
16. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis